Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant DNase I and transferrin f ...